Abbott Laboratories Corporation

Abbvie Inc.

Aventis Pharmaceuticals Inc.

Abbvie Bahamas Limited

Meena V Patel

Teodozyj Kolasa

William A Carroll

Michael J Dart

Xueqing Wang

Sridhar Peddi

Arturo Perez-Medrano

Jennifer M Frost

Derek W Nelson

Tongmei Li

Andrew O Stewart

Bo Liu

Steven P Latshaw

Jeffrey J Rohde

Pramila A Bhatia

Marlon D Cowart

Michael E Kort

Catherine M McCarty

Jerome F Daanen

Alan S Florjancic

Karin Rosemarie Tietje

Keith Brian Ryther

Megan E Gallagher

Lawrence A Black

Huaqing Liu

Anwer Basha

Mark A Matulenko

Jorge D Brioni

Michael J Coghlan

Steven Armen Boyd

David A DeGoey

John R Koenig

Gui-Dong Zhu

Tammie K Jinkerson

David M Stout

Marc J Scanio

Andrew Bogdan

David L Arendsen

Brian D Wakefield

Nicholas A Mort

Hillary M Peltier

Indrani W Gunawardana

Michael A Staeger

Jennifer C Freeman

Karin Rose Marie Tietje

Kraig Lartey

Kevin R Condroski

Gary A Flynn

Douglas Wade Beight

Alan M Warshawsky

Joseph P Burkhart

Michael D Meyer

Michael John Janusz

Kathleen Mortell

Henry Q Zhang

Ramalinga M Dharanipragada

Zhiren Xia

Kenneth M Engstrom

Joseph T Tsay

Arturo Perez Medrano

Tedozyi Kolasa

Ahmed A Hakeem

Jian Shen

Keith B Ryther

Jiu-Tsair Tsay

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and L, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as cannabinoid receptor ligands and uses thereof

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L, A, R, z, R, R, and Rare as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Compounds as cannabinoid receptor ligands

The present application relates to thiazolylidene containing compounds of formula (I) wherein R, R, R, R, Land A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A, A, R, X, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present application relates to cannabinoid receptor ligands of formula (I) wherein X, A, R, R, R, R, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and Lare defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R, R, R, R, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and Lare defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, 

The present invention provides for compounds of formula (I) wherein A, L, R, R, R, R, R, R, q1, and z are as defined in the specification, are prodrugs of CBreceptors ligands and as such are useful in the prevention and treatment of various diseases and conditions including, but not limited to, pain.

Prodrug compounds useful as cannabinoid ligands

The present invention relates to inhibitors of 11-&#x3b2;-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Amide and amidine derivatives and uses thereof

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R, R, R, R, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I) wherein A, E, L, R, R, Rand Rare as defined in the herein, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Disclosed herein are compounds of formula (I) wherein R, R, R, R, R, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.

Growing community of inventors

Green Oaks, IL, United States of America

Meena V Patel